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Oxidative stressBackground: Hyperglycemia-induced oxidative stress is one mechanism believed to underlie diabetic vascular
disease. We tested the hypothesis that diabetic subjects heterozygous for extracellular superoxide dismutase
(SOD3) R213G, which entails lower antioxidant capacity in tissues, have increased risk of cardiovascular disease
and heart failure.
Methods:We used the prospective Copenhagen General Population Study and Copenhagen City Heart Study and
genotyped 95,871 individuals for the rs1799895 R213G variation in the SOD3 gene, of which 4498 had diabetes.
We used national hospitalization and death registers to assess cardiovascular disease and heart failure.
Findings:Out of 95,871 individuals, we identiﬁed 93,521 R213G non-carriers (213RR, 97.5%), 2336 heterozygotes
(213RG, 2.4%) and 14 homozygotes (213GG, 0.01%). In diabetic subjects, the hazard ratio for cardiovascular
disease in R213G heterozygotes compared to non-carriers was 2.32 (95% CI 1·44–3.75), with a corresponding
hazard ratio in non-diabetic subjects of 0.97 (0·80–1.19) (p for interaction 0.002). For heart failure, the hazard
ratios in R213G heterozygotes compared to non-carriers were 2.19 (1.28–3.76) in diabetic and 0.68
(0.49–0.92) in non-diabetic subjects (p for interaction b 0.001).
Interpretation: Risk of cardiovascular disease and heart failure was higher in R213G heterozygotes versus non-
carriers in diabetic subjects, but not in non-diabetic subjects.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Cardiovascular disease is the leading cause of morbidity andmortal-
ity in individuals with diabetes, with a 2–4 fold higher risk of cardiovas-
cular disease and up to 3 fold higher risk ofmortality compared to those
without diabetes (Fox et al., 2004; Preis et al., 2009). Hyperglycemia-
induced oxidative stress with subsequent increase in oxidized biomo-
lecules and associated tissue damage is one mechanism believed to un-
derlie diabetic vascular disease (Schaffer et al., 2012; Fiorentino et al.,
2013). Furthermore, oxidative stress has been implicated in the athero-
sclerotic process aswell as inmyocardial damage (Maiolino et al., 2013;
Waddingham et al., 2015). As a result, myocardial damage may lead to
myocardial dysfunction and heart failure, a common diabetic complica-
tion that can develop independently of other cardiovascular risk factors
(Waddingham et al., 2015).
The extracellular superoxide dismutase enzyme (SOD3, EC-SOD) is
the major extracellular scavenger of superoxide anions and regulates
vascular superoxide anion levels by catalyzing the dismutation of super-
oxide into oxygen and hydrogen peroxide (McCord and Fridovich,
1969). SOD3 is mainly secreted by vascular smooth muscle cells and. Nordestgaard).
. This is an open access article undershows high afﬁnity for heparan sulfate proteoglycans, other sulfated
proteoglycans as well as type I collagen, and thus, is largely bound to
cell surfaces and extracellular matrix components in blood vessel
walls (Stralin et al., 1995; Oury et al., 1996; Petersen et al., 2005). The
tissue-bound form is believed to make up 90–99% of total SOD3
(Sandström et al., 1993). The SOD3 binding to heparin–heparan sulfate
molecules is electrostatic in nature andmediated through an extracellu-
lar matrix-binding domain, where a cluster of 6 positively charged
amino acids in position 210–215 in the C-terminal end forms the essen-
tial part (Sandstrom et al., 1992). A rare mutation in the extracellular-
binding domain of SOD3 at position 213 (arginine to glycine, R213G)
leads to decreased extracellularmatrix afﬁnitywith unaltered enzymat-
ic activity (Sandstrom et al., 1994). The decreased extracellular matrix
afﬁnity in R213G is likely caused by interruption of the ionic interaction
with heparin–heparan sulfate as well as by altered tertiary structure of
the enzyme, disrupting the collagen binding capacity (Petersen et al.,
2005). Consequently, R213G heterozygotes have up to 10-fold higher
plasma levels of SOD3 and blood vessel walls that are deﬁcient in the
SOD3 enzyme (Sandstrom et al., 1994).
We hypothesized that the antioxidant SOD3 enzyme in diabetic
subjects plays an especially important role in protecting the vessel
walls from oxidative damage. Thus, in the present study we tested the
hypothesis that diabetic subjects heterozygous for the SOD3 R213Gthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
2011C.J. Kobylecki et al. / EBioMedicine 2 (2015) 2010–2015genetic variation, which entails lower antioxidant capacity in tissues,
have increased risk of cardiovascular disease and heart failure. For this
purposewe genotyped 95,871 individuals from theDanish general pop-
ulation, of which 4498 had diabetes.
2. Methods
2.1. Study Population
We used the Copenhagen General Population Study (CGPS), initiat-
ed in 2003 with ongoing enrollment, and the Copenhagen City Heart
Study (CCHS), initiated in 1976–1978 with follow-up examinations in
1981–1983, 1991–1994, and 2001–2003 (Nordestgaard et al., 2007;
Thomsen et al., 2013). DNA was available in the CGPS and in the
1991–1994 and 2001–2003 examinations of the CCHS. For both studies,
individuals aged 20–100 years were invited randomly from the Danish
Civil Registration System to reﬂect the Danish general population. Par-
ticipation rate was 43% in the CGPS and 61% and 50% in the CCHS
1991–1994 and 2001–2003 examinations. The study was approved by
Herlev and Gentofte Hospital and by Danish Ethical Committees, and
was conducted according to the Declaration of Helsinki. Written, in-
formed consent was obtained from all participants. No subject was
lost to follow-up. We only included white individuals of Danish descent
with DNA available, a total of 87,030 individuals from the CGPS and
8841 from the CCHS.
2.2. Cardiovascular Disease and Heart Failure
Information on diagnosis of myocardial infarction (ICD8: 410,
ICD10: I21–I22), heart failure (ICD8: 427.09–427.11; ICD10: I50.0–
I50.9) and ischemic stroke (ICD8: 433–434, ICD10: I63) were collected
from 1977 through April 2013 from the national Danish Patient Registry
and the national Danish Causes of Death Registry, while the date of
death was obtained from the Danish Civil Registration System, as
done previously (Nordestgaard et al., 2007; Kamstrup et al., 2009;
Nordestgaard et al., 2012). The national Danish Causes of Death Registry
ranks main causes of death as well as contributing causes of death, as
reported by the attending physician, or physicians in a forensic or pa-
thology department. Cardiovascular disease was a composite of the
endpoints myocardial infarction, ischemic stroke and death from car-
diovascular disease, whichever endpoint came ﬁrst; a death was classi-
ﬁed as due to cardiovascular disease if one of three ranked causes of
death had a cardiovascular diagnosis (ICD8: 390–458, ICD10: I00–I99),
as done previously (Afzal et al., 2014).
2.3. Diabetes
Baseline diabeteswas deﬁned as self-reported diabetes of any type, a
hospital diagnosis of diabetes prior to the examination (ICD8: 249–250,
ICD10: E10, E11, E13, E14), non-fasting plasma glucose N11 mmol/L at
examination, or use of antidiabetic medication. Baseline and hospitali-
zation diabetes included both individuals with baseline diabetes and in-
dividuals who received a register diabetes diagnosis of any type during
follow-up. Baseline diabetes included 4498 individuals, of which 464
experienced a cardiovascular event prior to examination, leaving 4034
individuals for prospective analyses. For heart failure, 208 diabetic sub-
jects received a heart failure diagnosis prior to examination, leaving
4290 for prospective analyses. When individuals who did not have dia-
betes at the time of examination, but who received a diabetes diagnosis
during follow-up, were included, a total of 5145 individuals with diabe-
tes were eligible for prospective analyses.
2.4. Covariates
Baseline characteristicswere recorded froma self-administered ques-
tionnaire, a physical examination, and from blood samples. Participantsreported on smoking status (never, former, current) and if relevant,
number of years of smoking and daily tobacco consumption, from
which cumulative tobacco consumption in pack-years was calculated;
a pack-year was 20 cigarettes or equivalent smoked per day for one
year. Non-smokers were deﬁned as never or previous smokers. Self-
reported weekly alcohol intake was in units of ~12 g of alcohol. Further-
more, information on weekly physical activity (highest versus lowest
half of physical activity groups) and level of income (highest third versus
lowest two thirds), were obtained from the questionnaire. Body mass
index (BMI) was calculated frommeasured weight in kilograms divided
bymeasured height inmeters squared. Systolic blood pressurewasmea-
sured.We deﬁned hypertension as systolic blood pressure ≥ 140mmHg
(diabetics ≥ 130 mm Hg), diastolic blood pressure ≥ 90 mm Hg
(diabetics ≥ 80 mm Hg), or use of antihypertensive medication at time
of examination. The data was N99% complete and missing values for co-
variates were imputed according to age and sex to obtain a complete
dataset; however, if individuals with any missing data were excluded,
results were similar to those presented.
2.5. Laboratory Analyses
In the CGPS, we genotyped 87,030 individuals for the SOD3
rs1799895 (R213G) variant, using a TaqMan-based assay (Applied
Biosystems) and TaqMan GenoTyper v1.2 with a call rate of 99.3%. We
used DNA extracted from leukocytes in peripheral blood using the
Qiagen blood kit for DNA extraction. Genotypes were assigned in small-
er batches, each containing around 5500 individuals. In the CGPS, a total
of 87,718 individualswere attempted genotyped, 87,030 successfully. In
the CCHS, 8841 individuals out of 9251had been genotyped successfully
earlier, using polymerase chain reaction followed by restriction enzyme
digestion and agarose gel electrophoresis (RFLP), and all R213G carriers
(213RG and 213GG) had been reanalyzed and conﬁrmed by DNA se-
quencing (Juul et al., 2004). We used R213G heterozygotes and homo-
zygotes previously identiﬁed by RFLP and DNA sequencing as controls
for the TaqMan based assay.
Plasma concentrations of triglycerides, low-density lipoprotein
cholesterol, high-density lipoprotein cholesterol and high sensitive
C-reactive protein were measured with standard hospital assays
(Stender et al., 2013). Plasma SOD3 were measured using ELISA,
and results have been reported previously (Juul et al., 2004).
2.6. Statistical Analyses
We used Stata v.13.1. A chi-square test evaluated Hardy–Weinberg
equilibrium. Kruskal–Wallis test was used when comparing two sam-
ples. In all analyses, we combined the two studies in order to maximize
statistical power, and we adjusted for study.We pooled type 1 and type
2 diabetes because we did not have information on type of diabetes
from baseline questionnaire, and in the analyses that included hospital
diagnoses of diabetes, we upheld the pooling in order to maximize sta-
tistical power.
To examine the association between SOD3 R213G heterozygosity
and cardiovascular disease and heart failure, we used Cox proportional
hazards regression models with entry at examination date and age as
underlying time scale (referred to as age-adjusted), to estimate hazard
ratios with 95% conﬁdence intervals. Since all measured confounders
were evenly distributed among genotypes, we adjusted only for age. In-
teraction was tested for using a likelihood ratio test by introducing a
two-factor interaction term in a model also including both factors, e.g.
diabetes and R213G genotype. Follow-up ended April 2013 and those
dying or emigrating (n = 292) during follow-up were censored at
their death or emigration dates, respectively. Test for proportionality
of hazards over timewas performed using graphicalmethods and resid-
uals; no major violations were observed.
We calculated cumulative incidences of cardiovascular disease using
competing-risks survival regression with the method of Fine and Gray,
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for the competing risk of death. We used the STATA command stsplit
to split records at either date of examination (for baseline diabetes) or
at time of diagnosis of diabetes during follow-up, thus creating two
episodes for each subject that developed diabetes during follow-up, in
order to assess a possible different effect of the R213Gvariant on cardio-
vascular disease before and after occurrence of diabetes.3. Results
Among the 95,857 individuals from the CCHS and CGPS combined,
4498 (5%) had diabetes at baseline (Table 1). During follow-up, 4581
individuals (5%) experienced a cardiovascular event and 2736 (3%)
received a diagnosis of heart failure; for diabetic subjects, the corre-
sponding frequencies were 11% (427/4034) and 8% (332/4290). 1098
individuals experienced both cardiovascular disease and heart failure
during follow-up. The frequency of diabetes did not differ between
rs1799895 (R213G) heterozygotes and non-carriers, nor did any base-
line characteristics (Table 1); however, as previously shown plasma ex-
tracellular superoxide dismutase was 9-fold higher in heterozygotes
compared to non-carriers in the CCHS (Juul et al., 2004). R213G geno-
type frequencies were 97.5% (93,521/95,871) for non-carriers (213RR)
and 2.4% (2336/95,871) for R213G heterozygotes (213RG); R213G
homozygotes (213GG, 0.01%, 14/95,871) were excluded from the anal-
yses because of insufﬁcient statistical power for homozygotes alone. The
genotype distribution was in Hardy–Weinberg equilibrium (p = 0.88).
In the two studies combined, mean follow-up time was 6 years (min
0.003 years, max 21.5 years).Table 1
Baseline characteristics by SOD3 R213G (rs1799895) genotype stratiﬁed by baseline diabetes s
combined.
No baseline diabetes
Non-carriers (213RR) Heterozygote
N = 89,145 N = 2214
Men, (%) 39,463 (44) 980 (4
Age, years 57 (47–67) 57 (47–
Ever smoker 54,709 (61) 1336 (6
Height, m 1.7 (1.6–1.8) 1.7 (1.6–
Cumulative tobacco consumptiona, pack-years 16 (6–30) 16 (6–3
BMI, kg/m2 25 (23–28) 25 (23–
Alcohol consumption, units/week 8 (4–15) 8 (3–1
High income 34,138 (38) 886 (4
High physical activity (leisure time) 43,586 (49) 1078 (4
High physical activity (at work) 17,496 (20) 436 (2
Systolic blood pressure, mm Hg 139 (125–154) 139 (125–
LDL cholesterol, mmol/L 3.3 (2.6–3.9) 3.3 (2.6–
HDL cholesterol, mmol/L 1.6 (1.3–1.9) 1.6 (1.2–
Triglycerides, mmol/L 1.4 (0.97–2.1) 1.4 (0.95
CRP, mg/L 1.4 (1.0–2.4) 1.4 (1.0–
Cholesterol-lowering medication 7773 (9) 197 (9
Glucose, mmol/L 5.1 (4.7–5.6) 5.1 (4.7–
Insulin 0 0
Oral antidiabetic medications 0 0
Antihypertensive medication 15,505 (17) 375 (1
Cardiac medications 3792 (4) 88 (4
Anticoagulant therapyb 8691 (11) 219 (1
SOD3c, ng/mL (SD) 142 (46)⁎ 1285 (39
Continuous variables are shown as median (interquartile range). Categorical data are n (%). P
diagnosis of diabetes prior to examination, non-fasting plasma glucose N11mmol/L at examinat
HDL: high density lipoprotein. CRP: C-reactive protein. SOD3: superoxide dismutase 3.
a Among ever smokers only.
b Only available in the CGPS.
c Plasma SOD3 measured in the Copenhagen City Heart Study only, shown are mean (SD).
d Not signiﬁcant after Bonferroni correction for multiple testing.
⁎ N= 2057 individuals.
⁎⁎ N= 190 individuals.
⁎⁎⁎ N= 135 individuals.
⁎⁎⁎⁎ N= 11 individuals.3.1. Cardiovascular Disease
The cumulative incidence of cardiovascular disease in R213Ghetero-
zygoteswas higher than in non-carriers in diabetic subjects (sub-hazard
ratio: 2.18, 95% CI: 1.40–3.39, p = 0.001), but not in non-diabetic sub-
jects (SHR: 1.01 (0.82–1.24), p = 0.91) (Fig. 1). In Cox regression
models, the hazard ratios for cardiovascular disease in R213G heterozy-
gotes versus non-carriers were 2.32 (1.44–3.75) in diabetic subjects and
0.97 (0.80–1.19) in non-diabetic subjects (p for interaction = 0.002)
(Fig. 2). These hazard ratios were similar in the CCHS and CGPS sepa-
rately (Supplemental Fig. 1).
3.2. Heart Failure
The hazard ratios for heart failure in R213G heterozygotes versus
non-carriers were 2.19 (95% CI: 1.28–3.76) in diabetic subjects and
0.68 (0.49–0.92) in non-diabetic subjects (p for interaction b 0.001)
(Fig. 2). These hazard ratios were similar when analyzing the CCHS
and CGPS separately (Supplemental Fig. 1).
3.3. Sensitivity Analyses
In order to assess if R213G genotype interacted with other known
cardiovascular risk factors besides diabetes, we stratiﬁed analyses by
gender, age, smoking status, hypertension and cholesterol levels, but
no interactions except with diabetes were observed (Fig. 3). We found
a total of 14 R213G homozygotes (0.01%) that we did not include in
our analyses due to insufﬁcient statistical power for homozygotes
alone. However, in sensitivity analysis with R213G heterozygotes andtatus in the Copenhagen City Heart Study and the Copenhagen General Population Study
Baseline diabetes
s (213RG) p Non-carriers (213RR) Heterozygotes (213RG) p
N = 4376 N = 122
4) 0.93 2456 (56) 71 (58) 0.65
66) 0.32 66 (58–73) 65 (60–72) 0.99
0) 0.32 2959 (68) 74 (61) 0.11
1.8) 0.96 1.7 (1.6–1.8) 1.7 (1.6–1.8) 0.90
0) 0.25 25 (11–40) 28 (15–50) 0.08
28) 0.55 28 (25–32) 29 (26–33) 0.15
5) 0.15 8 (3–15) 8 (3–14) 0.84
0) 0.10 900 (21) 28 (23) 0.52
9) 0.85 1690 (39) 43 (35) 0.45
0) 0.94 694 (16) 22 (18) 0.52
154) 0.68 146 (132–160) 150 (139–164) 0.04d
4.0) 0.15 2.6 (1.9–3.3) 2.5 (1.9–3.3) 0.69
1.9) 0.86 1.4 (1.1–1.7) 1.4 (1.1–1.6) 0.43
–2.1) 0.21 1.8 (1.2–2.7) 1.9 (1.2–2.7) 0.71
2.4) 0.34 1.9 (1.2–3.7) 1.9 (1.2–3.5) 0.70
) 0.77 2053 (47) 57 (47) 0.97
5.6) 0.44 6.7 (5.5–9.6) 6.9 (5.5–9.6) 0.97
1.0 801 (18) 25 (20) 0.54
1.0 2030 (46) 68 (56) 0.04d
7) 0.58 2385 (55) 67 (55) 0.93
) 0.52 635 (15) 14 (12) 0.35
1) 0.87 1628 (41) 47 (42) 0.76
5)⁎⁎ b0.001 132 (36)⁎⁎⁎ 1110 (318)⁎⁎⁎⁎ b0.001
is from Kruskal-Wallis test. Baseline diabetes: self-reported diabetes of any type, hospital
ion, or use of antidiabeticmedication. BMI: bodymass index. LDL: low density lipoprotein.
Fig. 1. Cumulative incidence of cardiovascular disease by R213G SOD3 genotype, stratiﬁed
by diabetes status. Diabetes included baseline diabetes and diabetes during follow-up
from hospital registers. Baseline diabetes: self-reported diabetes, hospital diagnosis of
diabetes prior to examination, non-fasting plasma glucose N11 mmol/L at examination,
or use of antidiabetic medication. CVD: cardiovascular disease, composite endpoint of
cardiovascular death, myocardial infarction and ischemic stroke. Cumulative incidences
and subhazard ratios (SHR) are from competing risk regression (Fine and gray). Stsplit
at date of diabetes was used. For baseline diabetes, stsplit was at examination date. All
analyses were adjusted for age and study.
2013C.J. Kobylecki et al. / EBioMedicine 2 (2015) 2010–2015homozygotes pooled results were similar as when examining heterozy-
gotes alone (compare Supplemental Figs. 1 and 2). Additionally, when
individuals with type 1 diabetes (n = 393) at baseline were excluded,
results were similar (compare Supplemental Figs. 1 and 3). We could
not perform the analyses for type 1 diabetes separately, due to too few
R213G heterozygotes in this group.
4. Discussion
In this study of 95,857 white individuals from the Danish general
population, including 4498 with diabetes, risk of cardiovascular disease
and heart failure was higher in R213G heterozygotes versus non-
carriers in diabetic subjects, but not in non-diabetic subjects.
Hyperglycemia, oxidative stress, and cardiovascular disease could be
linked through different mechanisms. First, hyperglycemia may lead to
increased superoxide radical formation in vascular endothelial cells and
smooth muscle cells by NADPH oxidase through increased formation of
mitochondrial reactive oxygen species (ROS) (Paneni et al., 2013) and
advanced glycated end products (AGE) (Ago et al., 2011; Goldin et al.,
2006). Second, superoxide radicals and other ROS can react with nitric
oxide (NO), an important endothelial-derived vasodilator, decreasing
NO bioavailability and generating the powerful oxidant peroxynitrite.
This may lead to endothelial cell dysfunction or damage, which may
promote both atherosclerosis and heart failure (Davignon and Ganz,
2004; Joshi et al., 2014; Varga et al., 2015). Third, higher levels of ROScan increase oxidative modiﬁcations of LDL, which increase LDL uptake
by macrophages and lead to foam cell formation, a constituent of the
atherosclerotic plaque (Maiolino et al., 2013). Additionally, oxidized
LDL is thought to inﬂuence processes promoting the atherosclerotic
process including activation of macrophages, smooth muscle cells, and
platelet adhesion and aggregation (Maiolino et al., 2013). In diabetic
subjects, heart failure often develops independently of other cardiovas-
cular risk factors, suggesting a different pathogenesis of heart failure in
diabetic than in non-diabetic individuals (Joshi et al., 2014). One possi-
ble mechanism could be hyperglycemia-induced myocardial oxidative
stress leading to contractile dysfunction and microvascular changes
with myocardial remodeling and ﬁbrosis (Waddingham et al., 2015;
Orasanu and Plutzky, 2009). Taken together, it seems biologically plau-
sible that the SOD3 R213G variant, by drastically reducing tissue afﬁnity
of the SOD3 enzyme and leaving the vascular tissuewith low protection
against superoxide radicals, may increase the risk of cardiovascular dis-
ease and heart failure. Assuming this, the risk of cardiovascular disease
and heart failure would be even higher among R213G homozygotes
with diabetes, however, it is a rare genotype and we only identiﬁed 14
homozygotes, none ofwhich had diabetes. Thus, wewere not able to as-
sess the effect of R213G homozygosity on cardiovascular disease and
heart failure in diabetic subjects.
Previously, Mohammedi et al. found an association between the
promotor variant rs2284659 in the SOD3 gene, associated with higher
plasma and presumably higher tissue levels of SOD3, and lower cardio-
vascular morbidity and mortality with a hazard ratio of 0·75 (95% CI:
0.59–0.94) for myocardial infarction and of 0.83 (0.69–0.99) for cardio-
vascular mortality in three prospective cohorts including 3921 type 1
and type 2 diabetic patients (Mohammedi et al., 2015). These ﬁndings
indirectly support our ﬁndings as carriers of this promotor variant
should have higher protection against superoxide radicals and de-
creased risk of cardiovascular disease and mortality. Also supporting
our ﬁndings, Yamada et al. examined the association between the
SOD3 R213G variant and mortality in 456 hemodialysis patients, of
which 87had diabetes, and found a highermortality in R213Gheterozy-
gote diabetic subjects than in non-carriers (Yamada et al., 2000). In con-
trast, Ukkola et al. found no difference in prevalence of micro or
macroangiopathy in 8 R213G heterozygotes among 222 type 2 diabetic
subjects (Ukkola et al., 2001). However, with only a small number of
R213G heterozygotes, the power to detect a modest effect may have
been limited. Taken together, there seems to be emerging clinical evi-
dence that SOD3R213Gheterozygositymay affect prognosis speciﬁcally
among diabetic subjects. So far, only few cardiovascular risk factors se-
lective to diabetes have been described. Interestingly, a genetic varia-
tion in the region of the GLUL gene on chromosome 1q25, rs10911021,
has been robustly associatedwith coronary heart disease among diabet-
ic subjects in a 3-stage GWAS in 4188 type 2 diabetic patients. Further-
more, this genetic variant was shown to affect the glutamate and
glutaminemetabolism in endothelial cells, and it is possible that the in-
creased coronary heart disease risk in diabetic subjects could, at least in
part, be the result of a limited availability of the antioxidant glutathione
in these carriers (Qi et al., 2013).
A main strength of our study is the relative large number of R213G
heterozygotes with and without diabetes. Also, we were able to exam-
ine the association between R213G heterozygotes and cardiovascular
disease and heart failure in two large independent studies and found
similar results. However, potential limitations to our study should be
considered. First, we used cause of death in our composite endpoint of
cardiovascular disease and it is possible that death from coronary
heart disease is overestimated among diabetic subjects, due to physi-
cians' preexisting knowledge on the association between diabetes and
cardiovascular disease; importantly, however, this cannot explain the
ﬁndings in the present study as genotyping and ascertainment of car-
diovascular diseasewere done blinded to each other. Second, we pooled
type 1 and type 2 diabetes in order to maximize statistical power; yet,
results were similar after excluding type 1 diabetes. Furthermore, the
Fig. 2. Risk of cardiovascular disease and heart failure by SOD3 R213G genotype, stratiﬁed by diabetes status. Non-carriers: 213RR. Heterozygotes: 213RG. Baseline diabetes: self-reported
diabetes, hospital diagnosis of diabetes prior to examination, non-fasting plasma glucose N11 mmol/L at examination, or use of antidiabetic medication. A total of 3262 individuals had
experienced a cardiovascular event and 1188 had experienced heart failure prior to examination and were not included in the Cox regression with entry at examination. All estimates
were adjusted for age and study. Cardiovascular disease was the composite endpoint of cardiovascular death, myocardial infarction, and ischemic stroke. CI: conﬁdence interval.
2014 C.J. Kobylecki et al. / EBioMedicine 2 (2015) 2010–2015hypothesis that increased oxidative stress from hyperglycemia leads to
cardiovascular disease, and thus, that the two types of diabetes share a
common pathway to cardiovascular disease supports pooling type 1
and type 2 diabetes. Lastly, since all individuals were whites of Danish
descent, our results may not necessarily apply to other ethnicities; nev-
ertheless, this also minimizes the risk of population stratiﬁcation and
we are not aware of ﬁndings that suggest our results should not apply
to other ethnicities.
In conclusion, risk of cardiovascular disease and heart failure was
higher in R213G heterozygotes versus non-carriers in diabetic subjects,Fig. 3. Association between SOD3 R213G genotype and cardiovascular disease and heart failure
(213RR). Cardiovascular disease was the composite endpoint of cardiovascular death, myocard
hospital diagnosis of diabetes prior to examination, non-fasting plasmaglucose N11mmol/L at e
were adjusted for age and study. Cholesterol was plasma total cholesterol. CI: conﬁdence interbut not in non-diabetic subjects. These ﬁndings may have both biologi-
cal and clinical implications. First, this could provide further insight on
the pathophysiology of cardiovascular disease and heart failure in dia-
betes. Second, if our ﬁndings are replicated in future studies, SOD3
R213G heterozygosity could be used as a prognostic marker.Declaration of Interests
The authors declare to have no conﬂicts of interest., stratiﬁed by risk factors. R213G genotype was heterozygotes (213RG) versus non-carriers
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